Results 91 to 100 of about 18,252,794 (250)

Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer

Molecular Oncology, EarlyView.
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim, Maryam Aslam, Elouise Torruella, Alphons Sony, Asif Rahman, Simira Smith, Columba de la Parra, Moira Sauane   +7 more
wiley   +1 more source

Bridging the gap: a genetically validated avian chorioallantoic membrane platform for investigation of spontaneous circulating tumor cells

Molecular Oncology, EarlyView.
We established the avian chorioallantoic membrane (CAM) assay as a scalable in vivo model for studying circulating tumor cells (CTCs). Human gastrointestinal tumors spontaneously released genetically validated CTCs that were detected across multiple platforms, demonstrating that the CAM model provides an accessible tool for investigating early cancer ...
Dennis Roth, Rui P. L. Neves, Julia Geheb, Christian Ballmeyer, Nathalie Gaßmann, Kiki C. Andree, Monica Sudarsanam, Christiane Driemel, Celine Örencik, Andrè Franken, Eslam Elmaghraby, Sven H. Loosen, Roderburg Christoph, Sebastian Schoelch, Hans Neubauer, Wolfram T. Knoefel, Nikolas H. Stoecklein, Georg Fluegen   +17 more
wiley   +1 more source

Outcomes of usual chiropractic, harm & efficacy, the ouch study: study protocol for a randomized controlled trial [PDF]

, 2011
Background Previous studies have demonstrated that adverse events occur during chiropractic treatment. However, because of these studies design we do not know the frequency and extent of these events when compared to sham treatment.
Bruce F Walker, Clarke, B.R., Stomski Norman J, Stomski, N.J., Walker Bruce F, Hebert Jeff, Clarke, Brenton, Simon French, Walker, B.F., French, Simon, Walker, Bruce, Losco, Barrett, Hebert, Jeff, Stomski, Norman, French, S.D., Clarke Brenton R, Jeff Hebert, French Simon, Brenton R Clarke, Losco, B., Losco Barrett, Norman J Stomski, Barrett Losco, Hebert, J.J.   +23 more
core   +2 more sources

Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study

BMC Cancer, 2018
Background This study aimed to investigate the safety of sorafenib for the treatment of unresectable hepatocellular carcinoma in Chinese patients. Methods A subgroup of 345 Chinese patients from the international database of the Global Investigation of ...
Sheng-Long Ye, Jiamei Yang, Ping Bie, Shuijun Zhang, Xiaoping Chen, Fengyong Liu, Luming Liu, Jie Zhou, Kefeng Dou, Chunyi Hao, Guoliang Shao, Qiang Xia, Yajin Chen, Jijin Yang, Xiaxing Deng, Yunpeng Liu, Yunfei Yuan, Zhiren Fu, Keiko Nakajima, Zhengguang Lv   +19 more
doaj   +1 more source

Treatment with KCL‐286, a first‐in‐class retinoic acid receptor‐β (RARβ) agonist, ameliorates neuronal DNA damage and inflammation in a mouse model of Alzheimer's disease

FEBS Open Bio, EarlyView.
Repair of neuronal DNA damage in Alzheimer's disease by KCL‐286. (A) Amyloid‐β oligomers and plaques impair neuronal DNA repair pathways, leading to DNA double‐strand breaks and glial activation. (B) KCL‐286 activates RARβ/RXR signalling via retinoic acid response elements (RAREs), associated with increased BRCA1 expression, enhanced DNA repair and ...
Natasha Hill, Hassan Yousef Othman AlMuallim, Elouisa Maddock, Carl Hobbs, Earl Clarke, Maria B. Goncalves, Jonathan P. T. Corcoran   +6 more
wiley   +1 more source

Protocol for evaluation of the cost-effectiveness of ePrescribing systems and candidate prototype for other related health information technologies [PDF]

, 2014
Background: This protocol concerns the assessment of cost-effectiveness of hospital health information technology (HIT) in four hospitals. Two of these hospitals are acquiring ePrescribing systems incorporating extensive decision support, while the other
Coleman, Jamie J., Richard J Lilford, Aziz Sheikh, Samantha L Burn, Lilford, Richard J, Peter J Chilton, Jenkinson, David J, Jenkinson, David J., David J Jenkinson, Chilton, Peter J, Sheikh, Aziz, Blake, Laurence, Lilford, Richard, Burn, Samantha L, Hemming, Karla, Coleman, Jamie J, Girling, Alan J., Jamie J Coleman, Laurence Blake, Alan J Girling, Chilton, Peter J., Karla Hemming, Hemming, Karla; id_orcid, Coleman, Jamie J; id_orcid, Burn, Samantha L., Girling, Alan J, Lilford, Richard J.   +26 more
core   +2 more sources

From patient advocacy to patient‐driven research: Building active partnerships beginning at the bench to reach the bedside

FEBS Open Bio, EarlyView.
Research is strongest when conducted alongside patients, not just about them. Patient research organizations help integrate patient perspectives into research priorities, study design, and scientific meetings, leading to meaningful patient outcomes and development of relevant therapies.
Jenica H. Kakadia, Rachel Heilmann, Maximiliano Barrientos, Laura MacNeill, Ingrid Vallee, Sarah K. Schultz, Patrick O'Donoghue, Angelica A. Moresco, Victoria M. Siu, Ilka U. Heinemann   +9 more
wiley   +1 more source

An Estimate of the proportion of symptoms reported in Self-administered questionnaires that are captured as adverse drug events in an observational database [PDF]

, 2007
Purpose: This study was conducted to determine how frequently self-reported symptoms are captured as adverse drug events (ADEs) during chart abstraction.
Walmsley, S., Raboud, J., Bayoumi, A., Phillips, E.J., Sterling, S., Lesosky, M.   +5 more
core  

Treatment reactions and adverse events possibly related to the treatment.

, 2016
Treatment reactions and adverse events possibly related to the treatment.
Guoyu Zhou (3167277), Tianwen Gao (262800), Yi Zhao (14034), Yating Tu (3167292), Zhanchao Zhou (3167280), Qingshan Zheng (703370), Huilan Yang (3167289), Xiaoxi Lin (1789255), Jining Tao (3167295), Xuejun Zhu (1456465), Ying Gu (203149), Zhong Lu (1917088), Ping Tu (3167283), Hongfu Xie (3167286)   +13 more
core   +1 more source

Impact of immune‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors

Cancer Medicine
Background Immune checkpoint inhibitors have recently become the standard of care in the first‐line treatment of extensive‐stage small cell lung cancer.
Tadashi Nishimura, Hajime Fujimoto, Takumi Fujiwara, Kentaro Ito, Atsushi Fujiwara, Hisamichi Yuda, Hidetoshi Itani, Masahiro Naito, Shuji Kodama, Kazuki Furuhashi, Akihiko Yagi, Haruko Saiki, Taro Yasuma, Tomohito Okano, Atsushi Tomaru, Motoaki Tanigawa, Masamichi Yoshida, Osamu Hataji, Hidenori Ibata, Corina N. D'Alessandro‐Gabazza, Esteban C. Gabazza, Tetsu Kobayashi   +21 more
doaj   +1 more source